Lantheus Holdings (LNTH)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.33 (+0.37%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Lantheus Holdings (LNTH)
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Key Insights

Critical company metrics and information
  • Share Price

    $88.51
  • Market Cap

    $6.15 Billion
  • Total Outstanding Shares

    69.53 Million Shares
  • Total Employees

    834
  • Dividend

    No dividend
  • IPO Date

    June 25, 2015
  • SIC Description

    In Vitro & In Vivo Diagnostic Substances
  • Homepage

    https://www.lantheus.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities$-15.33 Million
Net Cash Flow$252.30 Million
Net Cash Flow From Financing Activities, Continuing$-15.33 Million
Exchange Gains/Losses$198000.00
Net Cash Flow From Investing Activities, Continuing$-231.48 Million
Net Cash Flow From Operating Activities, Continuing$499.31 Million
Net Cash Flow From Operating Activities$499.31 Million
Net Cash Flow, Continuing$252.50 Million
Net Cash Flow From Investing Activities$-231.48 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Income Tax Expense/Benefit$142.55 Million
Net Income/Loss Available To Common Stockholders, Basic$427.61 Million
Diluted Earnings Per Share$6.00
Costs And Expenses$926.64 Million
Income/Loss From Continuing Operations After Tax$427.61 Million
Benefits Costs and Expenses$926.64 Million
Research and Development$149.60 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Income/Loss From Continuing Operations Before Tax$570.16 Million
Cost Of Revenue$527.18 Million
Gross Profit$969.62 Million
Operating Income/Loss$480.59 Million
Operating Expenses$489.02 Million
Net Income/Loss Attributable To Parent$427.61 Million
Revenues$1.50 Billion
Other Operating Expenses$339.43 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Net Income/Loss$427.61 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Average Shares$143.40 Million
Basic Average Shares$138.60 Million
Basic Earnings Per Share$6.21

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Equity Attributable To Parent$1.18 Billion
Liabilities$869.92 Million
Equity Attributable To Noncontrolling Interest$0.00
Wages$35.74 Million
Liabilities And Equity$2.05 Billion
Other Non-current Assets$410.80 Million
Intangible Assets$173.61 Million
Other Current Assets$1.22 Billion
Accounts Payable$44.91 Million
Other Current Liabilities$703.42 Million
Assets$2.05 Billion
Fixed Assets$169.51 Million
Inventory$70.83 Million
Current Liabilities$784.08 Million
Equity$1.18 Billion
Noncurrent Liabilities$85.84 Million
Noncurrent Assets$753.92 Million
Current Assets$1.30 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.